Mid-Day Market Update: Gold Surges 2%; Neuronetics Shares Plunge
Midway through trading Wednesday, the Dow traded down 0.43% to 34,229.72 while the NASDAQ rose 0.40% to 14,524.02. The S&P also fell, dropping 0.10% to 4,346.21.
39 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target.
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
20 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday.
Regulus Therapeutics Reports Strategic Prioritization Of RGLS8429 Candidate For Treatment Of Autosomal Dominant Polycystic Kidney Disease
-Company will advance RGLS8429 supported by strong preclinical data and superior pharmacologic profile as compared to first-generation RGLS4326-
-Validating sections of IND-enabling toxicity studies for RGLS8429 have
Cantor Fitzgerald Initiates Coverage On Regulus Therapeutics with Overweight Rating, Announces Price Target of $2
Cantor Fitzgerald analyst Brian Cheng initiates coverage on Regulus Therapeutics (NASDAQ:RGLS) with a Overweight rating and announces Price Target of $2.
